New Treatments for Erosive Osteoarthritis: Emerging Options

Erosive osteoarthritis is one of the most destructive forms of hand arthritis, yet until recently it had almost no targeted treatments. Unlike garden-variety osteoarthritis, which wears cartilage down slowly, the erosive form actively breaks down bone in the finger joints, causing sharp flares of pain, swelling, and progressive deformity. Several experimental therapies are now moving through clinical trials, with one bone-protecting drug, denosumab, showing the strongest evidence so far that erosive joint damage can be slowed or even partially reversed. The treatment landscape is shifting, though most of these options remain years from routine clinical use.

What Makes Erosive Osteoarthritis Different

Erosive osteoarthritis (often shortened to EOA or EHOA for “erosive hand osteoarthritis”) targets the small joints in the fingers, particularly the ones closest to the fingertips and in the middle of the finger. On X-rays, these joints develop central erosions that give the bone a crumbling appearance, distinct from the sharply defined erosions seen in rheumatoid arthritis.¹ The condition overwhelmingly affects women around the time of menopause, and both hormonal shifts and genetics appear to drive its onset.²

What makes the disease so frustrating is that standard blood tests for inflammation usually come back normal, even while the joints are visibly swelling and eroding. The inflammation is local, not systemic, and it shows up in synovial tissue samples and on imaging rather than in routine bloodwork. Markers of bone breakdown, however, do tend to be elevated.² That mismatch between what patients experience and what their lab work shows has historically made it harder to get a diagnosis and harder to justify aggressive treatment.

At the joint level, the destructive cycle involves overactive bone-resorbing cells in the subchondral bone, the layer just beneath the cartilage. In the early stages, these cells ramp up activity, dissolving more bone than the body can rebuild. The result is enlarged bone marrow cavities, weakened subchondral architecture, and eventually bone cysts.³ That biology is directly relevant to the most promising new treatment approach.

Denosumab and Bone-Targeted Therapy

The treatment generating the most excitement for erosive hand osteoarthritis is denosumab, a drug already widely prescribed for osteoporosis. Denosumab works by blocking RANKL, the signaling molecule that tells the body to produce and activate the bone-resorbing cells responsible for erosions. The logic is straightforward: if excessive bone resorption is driving the damage, shutting down that process should slow or stop it.

A randomized, placebo-controlled phase 2a trial tested this idea and found that denosumab had genuine structure-modifying effects. Joints treated with denosumab showed significantly more remodeling, a sign that damaged bone was healing, compared to placebo. By 48 weeks, the structural improvement in the denosumab group was roughly 14 points higher on a scoring system that tracks joint anatomy, and the difference was statistically clear.⁴ Perhaps just as important, new erosive joints developed in only about 2% of denosumab-treated patients versus 7% of those on placebo, meaning the drug appeared to prevent the disease from spreading to unaffected joints.⁴

These are early-phase results from a single center, so the findings need confirmation in larger, multi-site trials. But the data represent the first real evidence that a drug can modify the structural course of erosive hand osteoarthritis.⁵ That is a meaningful milestone for a disease that has never had an approved disease-modifying therapy. The open question is whether structural improvement translates into less pain and better hand function over time. The trial showed bone healing, but symptom improvement was not the primary measure, and bone remodeling on imaging does not always map neatly onto how a person’s hands feel day to day.

TNF Inhibitors and the Inflammation Puzzle

Because erosive osteoarthritis involves local inflammation, researchers have tried repurposing drugs from rheumatoid arthritis, including tumor necrosis factor (TNF) inhibitors like adalimumab and etanercept. These drugs are powerful anti-inflammatory agents, so the hope was that tamping down joint inflammation would slow the erosive process. The results have been mixed in a specific and telling way.

A systematic review and meta-analysis of randomized controlled trials found that TNF inhibitors did not improve pain or hand function at any point within 12 months. They also failed to improve grip strength.⁶ On the symptom front, these drugs essentially did nothing. But the story gets more nuanced when you look at joint structure: there was evidence from individual trials that adalimumab reduced the progression of soft-tissue swelling and that etanercept slowed radiographic damage and reduced bone marrow lesions at 12 months.⁶

The etanercept trial is particularly instructive. In the full trial population, the drug did not beat placebo on pain. But in a pre-specified subgroup of patients who had both pain and confirmed inflammation at baseline, etanercept did show a meaningful pain reduction at one year. Joints in the etanercept group also showed more structural remodeling and fewer bone marrow lesions on MRI, especially in joints that were actively inflamed at the start.⁷ The takeaway is that TNF inhibitors might help a specific subset of erosive OA patients, those with active inflammatory flares, but they are not broadly effective enough to justify routine use.

Why IL-1 Blockade Fell Short

Interleukin-1 (IL-1) is another inflammatory molecule heavily implicated in joint destruction, and blocking it seemed like an obvious strategy. Lutikizumab, a dual antibody targeting both IL-1α and IL-1β, was tested in a phase 2a trial specifically in erosive hand osteoarthritis patients. The results were disappointing across the board: pain scores were no different between the drug and placebo at 16 weeks, and no imaging or clinical endpoints showed improvement.⁸

This was a genuine surprise to many researchers, because IL-1 is a central player in cartilage breakdown in lab studies. The failure suggests that erosive OA’s inflammatory component is driven more by bone resorption and mechanical damage than by the kind of sustained cytokine-mediated inflammation that IL-1 blockers target. It also reinforces the broader lesson from these trials: erosive osteoarthritis is not just “a little bit of rheumatoid arthritis in the hands,” and drugs designed for autoimmune joint disease do not automatically work here.

JAK Inhibitors in the Lab

Janus kinase (JAK) inhibitors are a newer class of anti-inflammatory drugs now widely used in rheumatoid arthritis and other autoimmune conditions. Two of these drugs, tofacitinib and baricitinib, have been tested in osteoarthritis tissue in the lab, though not yet in clinical trials specifically for erosive hand OA. In experiments using human joint cells from osteoarthritis patients, both drugs reduced inflammatory markers and tissue-degrading enzymes while also promoting cartilage-building activity.⁹

These are lab-dish findings and a long way from proof that taking a JAK inhibitor pill will help a person with erosive finger joints. But the results are interesting because JAK inhibitors hit a broader set of inflammatory pathways than TNF or IL-1 blockers do, which could theoretically address more of the disease’s complexity. The fact that these drugs also appeared to reduce fibrotic changes in joint tissue is a bonus, since fibrosis stiffens the joint lining and contributes to loss of motion.⁹ Clinical trials in erosive OA specifically would be needed to know whether these effects translate to patient benefit.

Wnt Pathway Modulators

One of the more novel drug development approaches in osteoarthritis targets the Wnt signaling pathway, a molecular cascade involved in joint tissue maintenance, repair, and inflammation. Lorecivivint (originally known as SM04690) is a small molecule injected directly into the joint that modulates this pathway. In animal models of osteoarthritis, it suppressed inflammatory cytokines and cartilage-degrading enzymes, increased cartilage thickness, and showed signs of actual cartilage regeneration.¹⁰ In laboratory studies, lorecivivint also promoted the development and function of mature cartilage-producing cells.¹¹

Lorecivivint has been tested primarily in knee osteoarthritis rather than erosive hand OA. Its relevance here is as a proof of concept: if a drug can regenerate cartilage and reduce local inflammation through a pathway distinct from TNF or IL-1, it opens the door to potential adaptation for the hand. Whether an intra-articular injection approach is practical for the tiny finger joints is another question entirely, and one that limits several promising therapies.

Nerve Growth Factor Inhibitors for Pain

While the drugs discussed above aim to slow or reverse joint damage, another class of treatment focuses squarely on pain. Nerve growth factor (NGF) is a protein that sensitizes pain-sensing nerves, and its levels are elevated in osteoarthritic joints. Antibodies that block NGF, including tanezumab, fulranumab, and fasinumab, have all demonstrated pain relief in randomized trials for moderate-to-severe osteoarthritis of the knee and hip.¹² Clinical studies found that NGF inhibitors substantially reduced joint pain and improved function compared with standard anti-inflammatory painkillers for durations of up to eight weeks.¹³

The catch is safety. NGF inhibitors were linked to cases of rapidly progressive joint destruction in some patients during trials, an alarming side effect that led to regulatory delays and restrictions. Tanezumab eventually received limited approval in some markets, with careful patient selection and dose limits. These drugs have not been specifically tested in erosive hand OA, but the pain-relief mechanism is relevant because erosive OA can cause severe, flare-driven pain that responds poorly to over-the-counter options. Whether the joint-safety concerns are more or less relevant in already-eroding finger joints is something researchers have not yet established.

Senolytic Therapies and Cellular Aging

One of the more forward-looking treatment ideas for osteoarthritis involves clearing out senescent cells, old, damaged cells that stop dividing but refuse to die. These cells accumulate in aging joints and secrete a cocktail of inflammatory molecules that damage surrounding tissue. Drugs or strategies that selectively kill senescent cells, called senolytics, are being explored as potential treatments.¹⁴

In one experimental approach, researchers identified a specific microRNA (miR-24) that was reduced in the cartilage of patients with osteoarthritis and cartilage defects. Restoring this molecule in lab-grown cartilage organoids reduced cellular senescence and promoted new cartilage growth. When delivered via a specially designed hydrogel scaffold in rats, the treatment improved cartilage repair and preserved joint function over 24 weeks with low inflammation.¹⁵ This is firmly in the preclinical stage, but the concept is compelling because it addresses a root cause of tissue deterioration rather than just blocking a single inflammatory molecule. For erosive OA, where the joint environment appears to be particularly hostile to healthy cells, targeting senescence could eventually complement bone-protecting drugs like denosumab.

Better Imaging Is Changing How Trials Work

A practical challenge in developing erosive OA treatments is measuring whether they actually work. Traditional X-rays can show erosions once they are established, but they miss early inflammatory changes and are slow to detect improvement. Ultrasound and MRI are changing that. Both can detect synovitis, bone marrow lesions, and early erosions before they are visible on X-ray, and a large systematic review of 32 studies confirmed that inflammatory features detected by ultrasound or MRI predict a higher risk of new radiographic damage.¹⁶

This matters for treatment development in two ways. First, it means future trials can enroll patients earlier in the disease course, when intervention is more likely to make a difference. Second, MRI-based endpoints are more sensitive to change, so trials can detect treatment effects in smaller groups over shorter periods. The denosumab and etanercept trials both used advanced imaging to demonstrate structural changes that X-rays alone would have underestimated. As imaging protocols become standardized across research centers, running larger multi-site trials for erosive OA becomes more feasible.

Genetic Clues Pointing Toward Precision Treatment

A 2023 meta-analysis identified four common genetic variants associated with erosive hand OA, all with unusually strong effects for a complex disease. Two of these variants, near genes called ALDH1A2 and MGP, had already been linked to hand osteoarthritis more broadly. But two others, near SPP1/MEPE and at the 6p24.3 chromosomal region, were specific to the erosive form and had not been connected to non-erosive OA at all.¹⁷

The SPP1/MEPE finding is especially interesting because both genes are involved in bone mineralization and remodeling, tying directly back to the excessive bone resorption that defines the erosive process. MGP encodes a protein that regulates calcium deposition in tissues, and variants in this gene could help explain why some people’s finger joints develop destructive erosions while others with similar levels of osteoarthritis do not. These genetic discoveries are not treatments themselves, but they could eventually help identify who is at highest risk for erosive progression and who is most likely to respond to bone-targeted therapies like denosumab.

The Role of Metabolic Health

Erosive osteoarthritis has traditionally been thought of as a mechanical and inflammatory problem, but emerging research suggests that metabolic health plays a bigger role than expected. Obesity is a risk factor for hand osteoarthritis even though the hands are not weight-bearing joints, which points to systemic inflammation rather than simple joint overloading. In obesity, fat tissue releases inflammatory molecules like IL-6 and TNF-α that can disrupt cartilage maintenance and accelerate joint breakdown throughout the body.¹⁸

This metabolic connection suggests that managing weight and metabolic conditions like diabetes or metabolic syndrome could slow the progression of erosive OA independently of any drug therapy. It also means that future treatment strategies might need to address not just local joint inflammation but the broader metabolic environment. Whether anti-inflammatory drugs targeting metabolic pathways could be useful in erosive OA specifically has not been tested, but the overlap between metabolic inflammation and joint destruction is an active area of investigation.

Non-Drug Approaches Still Matter

With so much attention on new drugs, it is worth noting that non-pharmacological strategies remain the backbone of erosive OA management for now. Exercise programs targeting hand strength and flexibility, done for about 20 minutes three times a week, show modest benefits for pain, function, and stiffness, though the quality of evidence remains low. Night-time splinting of the finger joints closest to the fingertips has also shown pain reduction and improved joint extension in controlled trials.¹⁹

Intra-articular injections, corticosteroids or hyaluronic acid delivered directly into affected finger joints, offer short-term symptom relief but lack long-term data. Investigational injectables including platelet-rich plasma and stem cells have been explored in small studies, but most are limited by tiny sample sizes and brief follow-up periods. For the time being, the best practical advice for someone living with erosive OA is to combine hand therapy and splinting with whatever symptomatic medication works, while watching the pipeline for the disease-modifying options now being tested. The denosumab data in particular may reshape clinical practice within the next few years if larger trials confirm the early structural benefits.

Cell-Based and Regenerative Therapies

Regenerative approaches using the body’s own cells are being studied for osteoarthritis broadly, though their application to erosive hand OA specifically remains early. Animal studies have shown that injecting adipose-derived stem cells or stromal vascular fraction, a mix of cells harvested from fat tissue, into osteoarthritic joints can promote cartilage regeneration.²⁰ Translating these results to human finger joints presents unique challenges: the joints are extremely small, the disease involves bone erosion rather than just cartilage wear, and delivering cells precisely into an already-damaged joint capsule is technically demanding. These therapies are likely to remain experimental for erosive OA for the foreseeable future, even as some clinics already offer similar procedures off-label for knee and hip arthritis.